![[ Beasley Allen Law Firm Logo ]](http://www.reglan-lawyer.net/wp-content/themes/system-unity/images/logo.png){kind=logo}
Participants needed for clinical trial on new GERD treatment
Researchers from the North Alabama Research Center based in Athens, Ala., are looking for people to participate in clinical trials for a potential new medication to treat gastrointestinal disease, also known as GERD. Persons age 18 to 70 who are still suffering from symptoms of GERD despite treatment with prescription medications are welcome to participate in the clinical trial. Participants must live within 50 miles of the clinic. Those interested can sign up at the Clinical Connection Web site here.
Sufferers of gastroesophageal reflux disease, also known as GERD, often experience symptoms such as heartburn and a sour taste in the mouth. But nearly half of all people with GERD have no symptoms except a chronic cough.
A team of researchers renowned for their work in colon cancer believe they may have found a better treatment for Barrett’s esophagus and esophageal cancer based on findings from their colon cancer research, according to 
The U.S. Fifth Circuit Court of Appeals has found in favor with a lower court that patients may sue generic drug makers under state law for failing to provide adequate warnings about potential side effects with their drugs. The ruling extends a 2009 U.S. Supreme Court ruling governing makers of name-brand drugs. The issue of whether generic drug companies should be held liable for not adequately warning consumers has divided several district courts, which can increase the odds of a Supreme Court review in the future, according to U.S. Circuit Judge 
More and more doctors are diagnosing fussy infants with gastroesophageal reflux disease, or GERD, leaving some critics worrying that doctors are over-diagnosing the condition to soothe exasperated mothers.
Swiss biotech group Addex Pharmaceuticals announced that its lead drug candidate met expectations in a mid-stage clinical trial in heartburn, setting the company up for a lucrative partnership with a bigger drug maker that would provide much-needed funds for the startup company.
The Food and Drug Administration (FDA) has approved a generic version of a drug for treating gastroesophageal reflux disease, or GERD, in adolescents and adults. Amneal Pharmaceuticals’ nizatidine oral solution was approved in the 15-mg-per-15-ml strength, and is a generic version of Axid, made by Braintree Laboratories. The medication belongs to a class of drugs known as histamine H2 blockers.
Findings from a new study on the causes of gastroesophageal reflux disease (GERD) may lead to new way of treating the condition. According to a team of researchers from the University of Texas Southwestern Medical Center, GERD, which causes painful chest pain and heartburn, may be caused by immune system cells causing inflammation. The study showed that gastroesophageal reflux in rats causes tissue in the esophagus to release immune chemicals called cytokines. Those cytokines attract inflammatory cells that cause the uncomfortable symptoms associated with heartburn and GERD.
Patients who suffer from gastroesophageal reflux disease (GERD) often have to give up their favorite foods because of bothersome symptoms, which can include chronic heartburn, acid reflux, difficulty swallowing and constant belching. Medications can help but they sometimes come with irritating side effects. But a new procedure is offering hope for patients who suffer from GERD.